CVR 42443670Private limited company (ApS)Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)FrederiksbergFounded 4 Jun 2021
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about Epoqe Pharma ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
5
CVR, Aug 2026
+2 (+66.7%) over 12 months
Gross profit
-8.6M
DKK, annual report Dec 2025
Result
-9.1M
DKK, annual report Dec 2025
Equity
44.1M
DKK, annual report Dec 2025
LUNDBECKFOND INVEST A/SCVR 21855545, 33.3% to under 50% of capital and votes, since 9 Jan 2025
Sofinnova Capital X33.3% to under 50% of capital and votes, since 19 Sep 2024
and 3 moreOperating company
Dandex estimate: 5 employees registered in 2026Mark Stephen Sumeraysince 2 Jun 2026
CVR 2185554533.3% to under 50% of capital and votesclass Præferenceanparternotified 28 Aug 2026since 9 Jan 2025
CVR 276595355% to under 10% of capital and votesclass Ordinære anparternotified 28 Aug 2026since 4 Jun 2021
CVR 417752035% to under 10% of capital and votesclass Ordinære anparternotified 28 Aug 2026since 15 Dec 2021
CVR 421987655% to under 10% of capital and votesclass Ordinære anparternotified 19 Sep 2024since 4 Jun 2021
33.3% to under 50% of capital and votesclass Præferenceanparternotified 28 Aug 2026since 19 Sep 2024
Holders of 5% or more, from the owner register. CVR records shares in bands, not exact figures.
CVR 3607049833.3% to under 50% of capital and votesnotified 14 Feb 202222 Nov 2021 to 14 Feb 2022
CVR 406200605% to under 10% of capital and votesnotified 19 Sep 202415 Dec 2021 to 19 Sep 2024
Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report a calibrated decision model reading the auditor's text, not registered by the company. Each label links to its definition.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
12 Oct 2023 to 12 Nov 2026.
4 Jun 2021 to 12 Nov 2026.
Aug 2026, monthly: 5 employees, 3 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Jun 2024 | Jul 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 5 | 4 | 3 | 4 | 5 | 5 | 5 | 4 | 4 | 6 | 5 | 5 |
| FTE | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 4 | 3 | 4 | 5 | 5 | 5 | 4 | 4 | 4 | 4 | 3 |
| Series | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's own headcount as CVR records it, not the annual report's average, which may cover a group. Monthly Aug 2023 to Aug 2026.
Latest Aug 2026, published 21 Oct 2026. Source: CVR employment series (Årsbeskæftigelse, Kvartalsbeskæftigelse, Månedsbeskæftigelse).
| Metric | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 | Dec 2025 |
|---|---|---|---|---|---|
| Gross profit | -17 | -19 | 1,273 | -13,720 | -8,599 |
| Operating profit | -17 | -19 | -173 | -16,893 | -11,006 |
| Result for the year | -18 | -15 | -136 | -13,944 | -9,050 |
| Equity | 133 | 118 | -18 | 30,042 | 44,145 |
| Total assets | 145 | 2,580 | 1,111 | 34,851 | 49,150 |
| Employees (average) | Not reported | Not reported | 2 | 3 | 3 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | Not reportednote 1 | n.m.note 2 | n.m.note 2 | -1,177.6% | Not reportednote 3 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | Not reportednote 4 | Not reportednote 4 | n.m.note 2 | 50% | Not reportednote 3 |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group. Not every period is a full year: Jun 2022 covers 13 months (4 Jun 2021 to 30 Jun 2022) and Dec 2025 covers 6 months (1 Jul to 31 Dec 2025). Changes against them compare periods of different length.
Credit metrics are Dandex calculations from the filed figures, not filed values; estimates are in grey with a note. Ratios are percentages. Gearing and interest coverage are multiples. Rows marked Pro hold a value in the Pro plan. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
Annual report Dec 2025
1 Jul 2025 to 31 Dec 2025, published 10 Mar 2026
Annual report Jun 2025
1 Jul 2024 to 30 Jun 2025, published 15 Sep 2025
Annual report Jun 2024
1 Jul 2023 to 30 Jun 2024, published 17 Jul 2024
Annual report Jun 2023
1 Jul 2022 to 30 Jun 2023, published 17 Oct 2023
Annual report Jun 2022
4 Jun 2021 to 30 Jun 2022, published 28 Oct 2022
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The rows marked Pro on this page hold values in the Pro plan. For Epoqe Pharma ApS, that is:
Have Pro? Sign in to see the values on this page.
Each registered value from the day it took effect, newest first.
From CVR, read 12 Nov 2026. Text such as the signing rule and purpose is shown as registered.
19 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.
Vedtægter ændret: 28.08.2026
Kapitalforhøjelsen er besluttet den 28.08.2026.
kr. 111.111,00, indbetalt kontant, kurs 33.639,75.
Kapitalen udgør herefter kr. 399.997,00.
Bestyrelse:
Fratrådte:
Anette Sams Nielsen, den 22.06.2026.
Tiltrådte:
Mark Stephen Sumeray, den 22.06.2026.
Direktion:
Fratrådte:
Anette Sams Nielsen, (adm. dir), den 02.06.2026.
Tiltrådte:
Mark Stephen Sumeray, (adm. dir), den 02.06.2026.
Vedtægter ændret: 21.11.2025
Kapitalforhøjelsen er besluttet den 21.11.2025.
kr. 68.888,00, indbetalt kontant, kurs 33.610,00.
Kapitalen udgør herefter kr. 288.886,00.
Vedtægter ændret: 08.10.2025
Direktion:
Fratrådte:
Jens Thostrup Bukrinski, den 31.07.2025.
Vedtægter ændret: 09.09.2025
Regnskabsår ændret til: 01.01 - 31.12
Omlægningsperiode: 01.07.2025 - 31.12.2025
Vedtægter ændret: 20.08.2025
Vedtægter ændret: 09.01.2025
Kapitalforhøjelsen er besluttet den 09.01.2025.
kr. 44.444,00, indbetalt kontant, kurs 33.574,38.
Kapitalen udgør herefter kr. 219.998,00.
Bestyrelse:
Fratrådte:
Anders Gaarsdal Holst, den 09.01.2025, Henrijette Elsebeth Richter, (formand), den 09.01.2025.
Tiltrådte:
Lars Gredsted, den 09.01.2025, Anders Gaarsdal Holst, (formand), den 09.01.2025, Henrijette Elsebeth Richter, den 09.01.2025.
Vedtægter ændret: 19.09.2024
Kapitalforhøjelsen er besluttet den 19.09.2024.
kr. 86.666,00, indbetalt kontant, kurs 33.557,00.
Kapitalen udgør herefter kr. 175.554,00.
Kapitalen er opdelt i klasser.
Bestyrelse:
Fratrådte:
Jan Bjerrum Bach, (formand), den 19.09.2024, Alejandra Maria Cristina Bonifacini Mørk, den 19.09.2024.
Tiltrådte:
Anette Sams Nielsen, den 19.09.2024, Henrijette Elsebeth Richter, (formand), den 19.09.2024.
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør eller af den samlede bestyrelse.
Vedtægter ændret: 28.08.2024
Vedtægter ændret: 27.06.2024
Ny adresse: c/o Symbion Frederiksberg, Nordre Fasanvej 215, 2000 Frederiksberg
Ny kommune: Frederiksberg
Vedtægter ændret: 08.12.2023
Vedtægterne er yderligere ændret
Vedtægter ændret: 12.10.2023
Selskabet tegnes af hele bestyrelsen i forening, af hele direktionen i forening, eller af bestyrelsens formand iforening med et direktionsmedlem.
Vedtægter ændret: 12.10.2023
Bestyrelse:
Tiltrådte:
Jan Bjerrum Bach, (formand), den 12.10.2023, Anders Gaarsdal Holst, den 12.10.2023, Alejandra Maria Cristina Bonifacini Mørk, den 12.10.2023.
Vedtægter ændret: 15.12.2021
Kapitalforhøjelsen er besluttet den 15.12.2021.
kr. 31.111,00, indbetalt kontant, kurs 299,98.
Kapitalen udgør herefter kr. 88.888,00.
Vedtægter ændret: 14.12.2021
Nyt navn: Epoqe Pharma ApS
Ny adresse: Ole Maaløes Vej 3, 2200 København N
Ny kommune: København
Nyt binavn: Patentselskabet af 31. maj 2021 ApS
Kapitalforhøjelsen er besluttet den 14.12.2021.
kr. 17.777,00, indbetalt kontant, kurs 100,00.
Kapitalen udgør herefter kr. 57.777,00.
Direktion:
Fratrådte:
Anette Nielsen, den 14.12.2021.
Tiltrådte:
Jens Thostrup Bukrinski, den 14.12.2021, Anette Nielsen, (adm. dir), den 14.12.2021.
Selskabet tegnes af to direktører i forening.
Revision:
Tiltrådte:
CVR-NR. 14119299 PKF MUNKEBO VINDELEV, STATSAUTORISERET REVISIONSAKTIESELSKAB, Hovedvejen 56, 2600 Glostrup, den 14.12.2021.
Formål ændret: Selskabets formål er at udvikle og markedsføre et eller flere lægemidler, herunder at drive forskning med henblik på at identificere, validere, udvikle og markedsføre lægemidler tillige med anden virksomhed, der står i forbindelse hermed.
Stiftelsesdato: 04.06.2021.
Virkningsdato: 04.06.2021.
Seneste vedtægtsdato: 04.06.2021.
Kapital:
kr. 40.000,00.
Kapitalklasser: Nej
Indbetalingsmåde: Indbetalt kontant kr. 40.000,00 til kurs 100,00, fuldt indbetalt.
Stiftere:
CVR-NR. 27659535 Helms & Sams ApS, Langs Hegnet 88, 2800 Kgs.Lyngby, den 04.06.2021, CVR-NR. 42198765 Edvince ApS, Adelgade 15, 1304 København K, den 04.06.2021.
Direktion:
Anette Nielsen, den 04.06.2021.
Selskabet tegnes af en direktør
Første regnskabsår:
04.06.2021 - 30.06.2022.
Regnskabsår:
01.07 - 30.06.
Formål:
Virksomhedens formål er at være holdingselskab for patenter som skal identificere, validere og udvikle lægemidler og i den forbindelse udarbejde og indlevere patentansøgninger samt arbejde med indlicensiering og bortlicensiering af patenter.
1 registered in CVR.
P-number 1027233534Nordre Fasanvej 215, 2000 Frederiksberg
No other current company drawn.
No other current company drawn.
